[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated 
Advanced Non-small Cell Lung Cancer]

Area of Science:

• Oncology
• Pharmacology
• Medical Research

Background:

• Lung cancer remains a major cause of cancer mortality globally.
• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard for EGFR-mutated advanced non-small cell lung cancer (NSCLC).
• Acquired resistance to EGFR-TKIs is a significant clinical challenge, limiting long-term efficacy.

Purpose of the Study:

• To review the efficacy and safety of combining EGFR-TKIs with angiogenesis inhibitors (A+T treatment) in advanced NSCLC.
• To explore the optimal target population and future prospects of A+T treatment.
• To clarify the benefits of A+T treatment across different generations of EGFR-TKIs compared to monotherapy.

Main Methods:

• Literature review of clinical trials involving EGFR-TKIs combined with angiogenesis inhibitors.
• Analysis of data on progression-free survival (PFS) and safety profiles.
• Synthesis of information on mechanisms of action and patient selection.

Main Results:

• Several clinical trials indicate that A+T treatment can enhance progression-free survival (PFS) in NSCLC patients.
• The specific benefits and safety profiles vary depending on the EGFR-TKI used in combination.
• Further research is needed to fully elucidate the advantages and optimal application of A+T therapy.

Conclusions:

• EGFR-TKI combined with angiogenesis inhibitors presents a promising strategy to overcome therapeutic resistance in advanced NSCLC.
• Understanding the nuances of different EGFR-TKIs and patient populations is crucial for maximizing treatment benefits.
• Continued investigation into A+T treatment is warranted to optimize outcomes for NSCLC patients.